SAN DIEGO, Feb. 27, 2014 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive
Officer of Neurocrine Biosciences, will be presenting at the Cowen
and Company 34th Annual Health Care Conference in
Boston.
The live presentation takes place on Tuesday, March 4 at 9:20am
ET (6:20am PT). The
presentation will be webcast and may be accessed on the Company's
website at http://www.neurocrine.com.
Listeners are encouraged to visit the website approximately 5
minutes prior to the presentation to download or install any
necessary software. A replay of the presentation will be
available on the website approximately one hour after the
conclusion of the event and will be archived for one month.
Neurocrine Biosciences, Inc. is a clinical stage drug discovery
company primarily focused on neurological and endocrine based
diseases and disorders. The Company discovers and develops
innovative pharmaceuticals, in diseases with high unmet medical
needs or where the existing drug classes are inadequate, through a
disciplined yet entrepreneurial process. Utilizing a portfolio
approach to drug discovery, Neurocrine has multiple small molecule
drug candidates at various stages of pharmaceutical development.
Neurocrine's two lead late stage clinical programs are elagolix, a
GnRH antagonist for women's health that is partnered with AbbVie
Inc., and a wholly owned VMAT2 inhibitor for the treatment of
movement disorders. Neurocrine intends to maintain certain
commercial rights to its VMAT2 inhibitor for evolution into a
fully-integrated pharmaceutical company. Neurocrine
Biosciences, Inc. news releases are available through the Company's
website via the internet at http://www.neurocrine.com.
SOURCE Neurocrine Biosciences, Inc.